PF-Atlas › Clinical Trials › NCT07654517
A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis
Pirfenidone 267 MG [Esbriet] · Phase 1
Registry ID
NCT07654517
Phase
Phase 1
Status
Not yet recruiting
Drug / intervention
Pirfenidone 267 MG [Esbriet]
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Start
2026-12-01
About this trial
Pirfenidone 267 MG [Esbriet] is evaluated in NCT07654517, a Phase 1 idiopathic pulmonary fibrosis study sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Current status: Not yet recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07654517 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.